Sinopharm, a state-controlled company, said its candidate had a 79 percent efficacy rate in interim late-stage trials, bringing a China-made vaccine a step closer to approval for mass use.
source https://www.nytimes.com/2020/12/30/business/china-vaccine.html
0 Comments